TNFRSF11A and neoplasm: Importantly, preclinical genetic mouse approaches evidence that the main immunomodulatory changes induced by denosumab in D-BEYOND—increased in TILs and CD8+ T cells—are replicated when RANK is lost specifically in the tumor compartment.